Figure 6.
Overview of the PROFICIO program for efficacy and safety of evolocumab (phase 2 and phase 3 clinical trials).55, 56, 57, 60, 62, 63, 69, 70, 71, 75, 78, 84, 85 Gray shading represents ongoing or planned studies. CVD, cardiovascular disease; FH, familial hypercholesterolemia; HeFH, heterozygous FH; HoFH, homozygous FH; LDL‐C, low‐density lipoprotein cholesterol; OLE, open‐label extension; SI, statin intolerance. aJapanese population. bEstimated enrollment.